Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to provide information about the bone anabolic properties and
absorption profile of Unigene's PTH Analog when administered as oral tablets over a period of
24 weeks to postmenopausal women with osteoporosis.